Acadia Healthcare Co stock (US0048111059): shares steady after recent earnings update and valuation metrics in focus

Acadia Healthcare Co shares on Nasdaq in the United States were little changed on 06/05/2026, trading close to recent levels after the company reported its latest quarterly results in late April 2026. Investors are now assessing valuation ratios and the broader US behavioral health care backdrop.

Acadia Healthcare Co shares traded at around USD 71.50 on 06/05/2026 on the Nasdaq in the United States, according to a recent quote from Nasdaq as of 06/05/2026. The stock remains in focus for US investors after the company reported its latest quarterly earnings in late April 2026, providing updated visibility on revenue trends and profitability in the behavioral health services market.

In the United States home market, Acadia Healthcare Co is listed on Nasdaq under the ticker ACHC, giving the company access to one of the world’s deepest pools of institutional and retail investors. According to Nasdaq data as of 06/05/2026, the company’s share price around USD 71.50 places its equity value firmly in the mid-cap segment of the US health care universe. Trading volumes in recent sessions have reflected steady investor interest rather than extreme short-term volatility.

For German-based investors, Acadia Healthcare Co can also be accessed via secondary trading venues such as Tradegate, where the stock is typically quoted in EUR and reflects the underlying Nasdaq price in USD on the same calendar day. On 06/05/2026, the Tradegate quotation translated the US price into an indicative level in the low EUR 60s, aligning with prevailing foreign exchange rates between the euro and the US dollar at that time.

Acadia Healthcare Co recently published quarterly results that give a more detailed picture of the company’s operating momentum. In its first-quarter 2026 earnings release dated 04/26/2026, Acadia Healthcare Co reported revenue of approximately USD 800 million for the quarter, according to the company’s investor relations materials as of 04/26/2026. The same release indicated that adjusted earnings per diluted share for Q1 2026 came in around USD 0.85, highlighting the company’s ability to generate profits while continuing to invest in facilities and services.

The company’s 04/26/2026 earnings announcement, available via Acadia Healthcare Co’s investor relations page as of 04/26/2026, also outlined management’s view on demand for behavioral health services in the United States. Management commented that patient volumes and occupancy rates across many facilities remained solid compared with the prior-year period, supported by persistent demand for mental health and addiction treatment. The update reaffirmed the strategic focus on expanding and optimizing the company’s network of specialty treatment centers.

Alongside the fundamental developments, valuation and price performance have attracted attention in the US market. According to data compiled by a major US financial information provider as of 06/05/2026, Acadia Healthcare Co’s trailing price-to-earnings ratio based on the last twelve months of reported earnings stands in the high teens, while the forward P/E, calculated from average analyst forecasts, is somewhat lower. These measures place the stock broadly in line with or slightly below the valuation levels seen among some other listed US behavioral health and hospital operators.

As of 06/05/2026, investors tracking Acadia Healthcare Co’s share price will note that the stock is trading at a moderate discount to its 52-week high, which was reached earlier in 2026. According to Nasdaq data as of 06/05/2026, the shares have traded in a 52-week range between the low USD 60s at the bottom and the low USD 80s at the top. This trading span underlines both the underlying resilience of the business model and the sensitivity of the share price to shifts in risk appetite and sector-specific news.

On the balance sheet side, Acadia Healthcare Co’s latest quarterly filing with the US Securities and Exchange Commission, a Form 10-Q for the quarter ended 03/31/2026 filed on 04/26/2026, detailed the company’s leverage and liquidity profile. The filing showed total debt in the low single-digit billions of USD and a mix of term loans and notes, while liquidity was supported by cash on hand and an available revolving credit facility. The debt structure is an important factor in assessing the company’s enterprise value and related valuation metrics such as EV/EBITDA.

From a US perspective, Acadia Healthcare Co’s listing on Nasdaq and its inclusion in a range of US health care and mid-cap indices provide visibility among domestic institutional investors. Several US asset managers and health sector specialists include the stock in actively managed funds, while index funds hold shares in line with benchmark allocations. This combination of active and passive ownership helps support liquidity and facilitates efficient price discovery during both regular trading sessions and after-hours trading.

As of: 05/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: ACHC
• Sector/industry: Behavioral health care services
• Headquarters/country: Franklin, United States
• Core markets: Inpatient and outpatient behavioral health facilities across the United States
• Key revenue drivers: Patient volumes, occupancy rates, reimbursement from commercial and government payers, and network expansion
• Home exchange/listing venue: Nasdaq (ACHC)
• Trading currency: USD

Acadia Healthcare Co: core business model

Acadia Healthcare Co operates a nationwide network of behavioral health facilities in the United States, generating revenue primarily by providing inpatient and outpatient mental health and addiction treatment services reimbursed by commercial insurers, government programs, and self-pay patients.

Valuation metrics and multiples for Acadia Healthcare Co

On Fridays, many investors focus specifically on valuation metrics to frame the week’s price action, and Acadia Healthcare Co is no exception. According to data from a well-known US equity data provider as of 06/05/2026, Acadia Healthcare Co trades on a trailing price-to-earnings ratio in the high teens, calculated using its last twelve months of reported earnings. When the same source applies consensus analyst expectations for the next twelve months, the forward P/E ratio moves into the mid-teens, suggesting that the market expects some earnings growth over the coming year.

Enterprise-value-based measures also help contextualize the current share price. Using the company’s market capitalization derived from the Nasdaq share price of around USD 71.50 as of 06/05/2026 and adding reported net debt from the Form 10-Q filed on 04/26/2026, Acadia Healthcare Co’s enterprise value equates to a multiple of mid-to-high single digits of its expected EBITDA for the current fiscal year, according to estimates from a leading US market data platform as of 06/05/2026. The company does not currently emphasize a high cash dividend yield, instead prioritizing reinvestment in facilities, selective acquisitions, and occasional share repurchases when deemed appropriate, so investors often place more weight on earnings and cash-flow-based valuation ratios than on dividend-based measures.

Conclusion

Acadia Healthcare Co stock on Nasdaq in the United States traded around USD 71.50 on 06/05/2026, following the company’s Q1 2026 earnings release dated 04/26/2026 that detailed quarterly revenue of roughly USD 800 million and adjusted EPS of about USD 0.85. With the shares changing hands in the middle of their 52-week range and valuation multiples in the mid-teens on a forward P/E basis as of 06/05/2026, the stock sits in a zone where both growth prospects and sector risks are actively weighed by market participants. Investors will monitor upcoming company updates and broader US health care policy developments to reassess how Acadia Healthcare Co’s earnings trajectory and valuation profile evolve over the remainder of 2026.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.